Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to \< 15 years old, with Sickle Cell Disease. The primary objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound) measurements in SCD participants in this age range.
Epistemonikos ID: 3e6476e0d22d070546f90c5c7aeab59395c53d90
First added on: May 06, 2024